Oncimmune's strategic pivot aims for robust growth in 2024 - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings 00:00:00

Share On Facebook Share On Twitter

Martin brings 30 years corporate finance and business development experience in the CRO, healthcare and pharmaceutical sectors to his role as CEO at Oncimmune. Most recently, Martin was a Global SVP Business Development at Owkin, where he managed all of the commercial teams in the USA and Europe and led new strategic research partnerships.

Recent Videos